U.S. FDA approves Travere Therapeutics kidney disorder drug
Reuters
Published Feb 17, 2023 04:36PM ET
Updated Feb 17, 2023 06:50PM ET
By Sriparna Roy, Nandhini Srinivasan and Khushi Mandowara
(Reuters) -Travere Therapeutics said on Friday the U.S. health regulator has granted accelerated approval to its drug to treat a type of chronic kidney disease, IgAN, in adults with a high risk of advancing to kidney failure.
Shares of the drugmaker were up 2.8% at $18.32 after market
The drug, with the brand name Filspari, comes with a boxed warning for inflammation in liver and birth defects. Patients will need to be tested for liver toxicity before starting the drug.
During the treatment, patients would be profiled for toxicity data on a monthly frequency for the first 12 months, and then once in every three months.
The approval pits Filspari against Calliditas Therapeutics' Tarpeyo, which was greenlit by the U.S. Food and Drug Administration in December 2021.
Filspari will be priced at $9,900 per month, making it cheaper than Tarpeyo's cost of $14,160 per month or $170,000 a year. At least three analysts expected the list price of Travere's drug to be between $70,000 and $100,000 a year.
Jefferies analyst Maury Raycroft estimates that for the year, Travere could make about $35 million in 2023 from sales of the kidney drug. It is expected to have peak sales of $745 million in the United States.
Travere expects to launch the drug by end of the month through its specialty distributors and specialty pharmacies in the United States.
IgA nephropathy (IgAN), also called Berger's disease, occurs when immunoglobulin A antibodies, proteins made by the immune system to protect the body, build up in the kidneys, damaging tissues and leaking blood and protein into urine.
The tissue damage affects the filtering ability of the kidneys, and eventually progresses to end-stage kidney failure. Analysts estimate that about 150,000 patients suffer from this condition in the U.S.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.